PATIENT STORIES: THE USE OF NOVEL ANTI-FIBROTICS, PIRFENIDONE AND NINTEDANIB, IN THE MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS, IPF

被引：0
|
作者：
Enston-Newall, S. [1 ]
机构：
[1] Cardiff Univ, Cardiff, S Glam, Wales
来源：
THORAX | 2017年 / 72卷
关键词：
D O I：
10.1136/thoraxjnl-2017-210983.443
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
M21
引用
收藏
页码：A247 / A248
页数：2
相关论文
共 50 条
  • [21] Late Breaking Abstract - Safety of combined pirfenidone (PFD) and nintedanib (NIN) in patients with idiopathic pulmonary fibrosis (IPF)
    Flaherty, Kevin
    Fell, Charlene D.
    Huggins, J. Terrill
    Nunes, Hilario
    Sussman, Robert
    Valenzuela, Claudia
    Petzinger, Ute
    Stauffer, John. L.
    Gilberg, Frank
    Bengus, Monica
    Wijsenbeek, Marlies
    EUROPEAN RESPIRATORY JOURNAL, 2017, 50
  • [22] Outcomes in Patients Receiving Nintedanib or Pirfenidone for Idiopathic Pulmonary Fibrosis
    Cottin, V.
    Spagnolo, P.
    Bonniaud, P.
    Nolin, M.
    Dalon, F.
    Kirchgassler, K.
    Chia, J.
    Kamath, T. V.
    Van Ganse, E.
    Belhassen, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [23] SAFETY OF COMBINED PIRFENIDONE AND NINTEDANIB IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS
    Flaherty, K. R.
    Fell, C. D.
    Huggins, J. T.
    Nunes, H.
    Sussman, R.
    Valenzuela, C.
    Petzinger, U.
    Stauffer, J. L.
    Gilberg, F.
    Bengus, M.
    Wijsenbeek, M.
    THORAX, 2017, 72 : A253 - A254
  • [24] Outcomes in patients receiving nintedanib or pirfenidone for idiopathic pulmonary fibrosis
    Cottin, Vincent
    Spagnolo, Paolo
    Bonniaud, Philippe
    Nolin, Maeva
    Dalon, Faustine
    Chia, Jenny
    Kirchgassler, Klaus
    Kamath, Tripthi
    Van Ganse, Eric
    Belhassen, Manon
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 121 - 121
  • [25] TRENDS IN NINTEDANIB AND PIRFENIDONE UTILIZATION FOR IDIOPATHIC PULMONARY FIBROSIS IN AUSTRALIA
    Cox, I
    De Graaff, B.
    Corte, T.
    Glaspole, I
    Chambers, D.
    Moodley, Y.
    Teoh, A.
    Walters, E.
    Palmer, A.
    RESPIROLOGY, 2021, 26 : 92 - 92
  • [26] COST-EFFECTIVENESS ANALYSIS OF PIRFENIDONE TABLETS COMPARED WITH NINTEDANIB FOR IDIOPATHIC PULMONARY FIBROSIS (IPF) TREATMENT IN TURKEY
    Erdogan-Ciftci, E.
    Yanik, L.
    Ersoy, Akyol B.
    Safak, K.
    Thuresson, P. O.
    VALUE IN HEALTH, 2019, 22 : S851 - S851
  • [27] Characteristics of patients with idiopathic pulmonary fibrosis (IPF) initiating nintedanib or pirfenidone treatment compared with untreated patients in the US
    Near, Aimee M.
    Burudpakdee, Chakkarin
    Wallace, Laura
    Hartmann, Nadine
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 163 - 164
  • [28] Safety Of The Combined Use Of Pirfenidone And Nintedanib In Patients With Idiopathic Pulmonary Fibrosis (ipf): Results From An Interim Analysis After 12 Weeks
    Flaherty, K. R.
    Sussman, R.
    Pesci, A.
    Nunes, H.
    Acosta, O.
    Petzinger, U.
    Stauffer, J.
    Gilberg, F.
    Bengus, M.
    Lancaster, L. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [29] Colitis Associated with Nintedanib Therapy for Idiopathic Pulmonary Fibrosis (IPF)
    Oda, Keishi
    Matsunaga, Takafumi
    Sennari, Konomi
    Yatera, Kazuhiro
    INTERNAL MEDICINE, 2017, 56 (10) : 1267 - 1268
  • [30] Real-World Evaluation of the Impact of the Anti-fibrotics in Patients with Idiopathic Pulmonary Fibrosis and Other Fibrotic Lung Diseases
    Dempsey, T. M.
    Thao, V.
    Sangaralingham, L.
    Limper, A. H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
12345